Wednesday, December 12, 2018

GenEdit Finds $8.5M For Gene Therapeutics

Berkeley-based GenEdit, which develops polymer nanoparticle technology platform for non-viral-based delivery of gene therapeutics, said on Tuesday that it has raised $8.5M in a seed funding round. The funding was led by Data Collective Bio (DCVC Bio) and SK Holdings and also included prior investors Sequoia Capital and Bow Capital. As part of the funding, Kiersten Stead, Ph.D. of DCVC Bio, and Matthew Rabinowitz, Ph.D., of Natera have both joined the company's board of directors. GenEdit is a spinout of the University of California, Berkeley, and its co-founders include three UC Berkeley scientists, including Kunwoo Lee, Hyo Min Park, and Niren Murthy.